Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the

Young Sup Woo1, Hyun Kook Lim1, Sheng-Min Wang1

  • 1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea.

Insights

Many studies link depression and type 2 diabetes (T2DM). Certain anti-diabetic drugs show antidepressant effects, possibly by targeting shared molecular pathways. This review explores these connections and potential treatments.

Area of Science:

  • Endocrinology
  • Neuroscience
  • Psychiatry

Background:

  • Type 2 diabetes (T2DM) and depression share underlying molecular pathways, including insulin resistance.
  • Insulin resistance disrupts molecular pathways, contributing to both metabolic disorders and depression.
  • Epidemiological and experimental studies suggest a strong connection between T2DM and depression.

Purpose of the Study:

  • To review clinical trials on the antidepressant effects of anti-hyperglycemic agents.
  • To explore the molecular mechanisms linking insulin resistance amelioration and depressive symptom improvement.
  • To propose an integrative perspective on the pathophysiology of depression.

Main Methods:

  • Review of clinical trial reports on specific anti-hyperglycemic medications.
  • Examination of medications including insulin, metformin, GLP-1 receptor agonists (GLP-1RA), and PPAR-γ agonists.
  • Brief consideration of molecular mechanisms involved.

Main Results:

  • Several anti-hyperglycemic agents have demonstrated antidepressant properties in clinical trials.
  • These effects are likely mediated by actions on brain targets involved in shared pathophysiology.
  • Evidence suggests a link between improved insulin sensitivity and reduced depressive symptoms.

Conclusions:

  • Anti-hyperglycemic agents may offer a novel therapeutic avenue for depression.
  • Understanding shared pathophysiology can lead to integrated treatment strategies.
  • Further research into molecular mechanisms is warranted for developing targeted therapies.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
500
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
5.9K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.9K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
648
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
434